More information
Description
The project aims to develop a standardized, safe and efficient method for curing dry age-related macular degeneration (AMD) - the most frequent cause of visual impairment that currently lacks treatment. The work will bring promising retina pigment epithelial (RPE) cell research to a clinical trial using patient-derived stem cell therapy. The Specific aims are focused at: 1) isolation, cultivation and optimization of human RPE cells, primary hRPEs and induced pluripotent stem cell (iPSC)-derived RPEs; 2) preparation of nanofibrous scaffold; 3) transplantation of hRPE-covered scaffolds in the subretinal space; 4) non-invasive (OCT, mfERG) and end-stage cell and tissue characterization (IHC, tEM); 5) establishment of good manufacturing practice (GMP) protocols and clinical-grade cell banking.
Summary of project results
The project aimed to address the lack of treatment for dry age-related macular degeneration (AMD), the most frequent cause of visual impairment. The objective of the project was to find treatment to slow down or cure this condtition, which impacts tens of millions people worldwide.
The project developed a standardized, safe, and efficient method for curing dry AMD using patient-derived stem cell therapy. The project worked on the isolation, cultivation, and optimization of human RPE (retinal pigment epithelium) cells, preparation of nanofibrous scaffold and transplantation of hRPE-covered scaffolds in the subretinal space.
This project made significant progress in growing retinal cells for potential eye treatments, opening possibilities for personalized therapies. Researchers refined methods for cultivating retinal cells, achieving efficient growth and transfer to a membrane that better mimics the eye''s natural environment. Furthermore, the team successfully transplanted these lab-grown cells into minipigs, demonstrating the potential for future human applications. Finally, they established procedures for storing these cell-laden membranes for consistent and readily available treatments. The beneficiaries of this project include people with AMD, researchers, and medical professionals.
Summary of bilateral results
The bilateral collaboration has delivered significant results, demonstrating a strong consortium with effective knowledge exchanges and smooth progress. The project’s involvement in the COST HAPLO IPS action ensures continuity and opens opportunities for further development.